Pneumonectomy for broncho-pulmonary carcinoids: a single centre analysis of surgical approaches and patient outcomes.

lung cancer neuroendocrine tumors outcomes perioperative management pneumonectomy survival analysis

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 07 02 2024
accepted: 09 07 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 8 8 2024
Statut: epublish

Résumé

Pneumonectomy is a radical surgical procedure associated with significant morbidity and mortality. Its application in the context of pulmonary neuroendocrine tumours, including carcinoid tumours, requires meticulous preoperative planning and intraoperative precision. This study aims to assess the safety and efficacy of pneumonectomy in the management of these rare and challenging neoplasms. A retrospective analysis of patients who underwent pneumonectomy for pulmonary carcinoid tumours at our institution over a specified period was conducted. Data regarding patient demographics, tumour characteristics, surgical techniques, intraoperative complications, perioperative management, and long-term outcomes were collected and analysed. Between March 2001 and October 2022, 21 patients (7 male, 14 female) with carcinoid tumours underwent pneumonectomy on a total of 459 surgical operations for carcinoid. Preoperative bronchoscopic procedures were conducted in 90.4% of cases, leading to histological diagnoses for most. The median hospital stay was eight days, with no reported perioperative deaths. Median follow-up after surgery was 73 months, with a five-year overall survival of 65.4 months. Recurrences occurred in 28.6% of cases, primarily in atypical carcinoids. Despite the rarity of bronchial carcinoids, pneumonectomy is effective for low-grade malignancies, demonstrating positive short-and long-term outcomes. Radical lymph node dissection is fundamental in pathological staging and overall survival.

Sections du résumé

Background UNASSIGNED
Pneumonectomy is a radical surgical procedure associated with significant morbidity and mortality. Its application in the context of pulmonary neuroendocrine tumours, including carcinoid tumours, requires meticulous preoperative planning and intraoperative precision. This study aims to assess the safety and efficacy of pneumonectomy in the management of these rare and challenging neoplasms.
Methods UNASSIGNED
A retrospective analysis of patients who underwent pneumonectomy for pulmonary carcinoid tumours at our institution over a specified period was conducted. Data regarding patient demographics, tumour characteristics, surgical techniques, intraoperative complications, perioperative management, and long-term outcomes were collected and analysed.
Results UNASSIGNED
Between March 2001 and October 2022, 21 patients (7 male, 14 female) with carcinoid tumours underwent pneumonectomy on a total of 459 surgical operations for carcinoid. Preoperative bronchoscopic procedures were conducted in 90.4% of cases, leading to histological diagnoses for most. The median hospital stay was eight days, with no reported perioperative deaths. Median follow-up after surgery was 73 months, with a five-year overall survival of 65.4 months. Recurrences occurred in 28.6% of cases, primarily in atypical carcinoids.
Conclusion UNASSIGNED
Despite the rarity of bronchial carcinoids, pneumonectomy is effective for low-grade malignancies, demonstrating positive short-and long-term outcomes. Radical lymph node dissection is fundamental in pathological staging and overall survival.

Identifiants

pubmed: 39114309
doi: 10.3389/fonc.2024.1383352
pmc: PMC11303279
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1383352

Informations de copyright

Copyright © 2024 Diotti, Bertolaccini, Girelli, Uslenghi, Donghi, Guarize, Spada, Fazio and Spaggiari.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Cristina Diotti (C)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Luca Bertolaccini (L)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Lara Girelli (L)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Clarissa Uslenghi (C)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Stefano Maria Donghi (SM)

Division of Interventional Pulmonology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Juliana Guarize (J)

Division of Interventional Pulmonology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Francesca Spada (F)

Division of Neuroendocrine and Digestive Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Nicola Fazio (N)

Division of Neuroendocrine and Digestive Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Lorenzo Spaggiari (L)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Classifications MeSH